Weekly epirubicin as salvage therapy inpatient with gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Cereda, S. [1 ]
Rognone, A. [1 ]
Mazza, E. [1 ]
Fugazza, C. [1 ]
Ceraulo, D. [1 ]
Ghidini, M. [1 ]
Villa, E. [1 ]
Reni, M. [1 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [1] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Villa, Eugenio
    Cereda, Stefano
    Mazza, Elena
    Vigano, Maria Grazia
    Vitali, Giordano
    Rognone, Alessia
    Di Carlo, Valerio
    Reni, Michele
    ANNALS OF ONCOLOGY, 2007, 18 : 15 - 15
  • [2] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Cereda, S.
    Reni, M.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (04) : 509 - 512
  • [3] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Cereda, S.
    Mazza, E.
    Vigano, M.
    Passoni, P.
    Balzano, G.
    Zerbi, A.
    Staudacher, C.
    di Carlo, V.
    Reni, M.
    ANNALS OF ONCOLOGY, 2007, 18 : VII113 - VII113
  • [4] Paclitaxel as a Salvage Chemotherapy in Patients With Gemcitabine-Refractory Pancreatic Cancer
    Maeda, S.
    Motoi, F.
    Kawaguchi, K.
    Onogawa, T.
    Morikawa, T.
    Okaue, A.
    Takadate, T.
    Rikiyama, T.
    Katayose, Y.
    Egawa, S.
    Unno, M.
    PANCREAS, 2009, 38 (08) : 1024 - 1024
  • [5] Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancer
    Cereda, S.
    Rognone, A.
    Mazza, E.
    Fugazza, C.
    Ceraulo, D.
    Villa, E.
    Reni, M.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (06) : 698 - 700
  • [6] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer : Is There a Standard?
    Almhanna, Khaldoun
    Kim, Richard
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1176 - 1183
  • [7] Salvage chemotherapy of fixed dose rate gemcitabine and S-1 combination therapy (FGS) for gemcitabine-refractory advanced pancreatic cancer
    Kasuga, A.
    Okano, N.
    Naruge, D.
    Kitamura, H.
    Takasu, A.
    Nagashima, F.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S633 - S634
  • [8] Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
    Nakachi, Kohei
    Furuse, Junji
    Ishii, Hiroshi
    Suzuki, Ei-ichiro
    Yoshino, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (02) : 114 - 120
  • [9] Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
    Kim, Jung Hoon
    Lee, Sang-Cheol
    Oh, Sung Yong
    Song, Seo-Young
    Lee, Namsu
    Nam, Eun Mi
    Lee, Soonil
    Hwang, In Gyu
    Lee, Hyo Rak
    Lee, Kyu Taek
    Bae, Sang-Byung
    Kim, Han Jo
    Jang, Joung Soon
    Lim, Do Hyoung
    Lee, Hyun Woo
    Kang, Seok Yun
    Kang, Jung Hun
    CANCER COMMUNICATIONS, 2018, 38
  • [10] Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
    Kipps, Emma
    Young, Kate
    Starling, Naureen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (03) : 159 - 170
12345